OSL
vs
S
S&P/ASX 300
OSL
Over the past 12 months, OSL has underperformed S&P/ASX 300, delivering a return of -68% compared to the S&P/ASX 300's +15% growth.
Stocks Performance
OSL vs S&P/ASX 300
Performance Gap
OSL vs S&P/ASX 300
Performance By Year
OSL vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Oncosil Medical Ltd
Glance View
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in North Sydney, New South Wales. The company went IPO on 2005-08-15. The firm is focused on unresectable locally advanced pancreatic cancer (LAPC). The firm's lead product, OncoSil, is a single-use brachytherapy internal radiation device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. The OncoSil consists of microparticles that contain a radioisotope phosphorous-32 and a formulated diluent, which acts as a carrier to facilitate the implantation of the microparticles into the target tissue. The company enables doctors to target a greater radiation dose directly to the tumor, while sparing surrounding critical organs. The OncoSil device is used for the treatment of unresectable LAPC and is used in conjunction with chemotherapy.
